Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

The transplant iron score as a predictor of stem cell transplant survival.

Storey JA, Connor RF, Lewis ZT, Hurd D, Pomper G, Keung YK, Grover M, Lovato J, Torti SV, Torti FM, Molnár I.

J Hematol Oncol. 2009 Oct 24;2:44. doi: 10.1186/1756-8722-2-44.

2.

Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.

Kim IH, Moon JH, Lim SN, Sohn SK, Kim HG, Lee GW, Kim YS, Lee HS, Kwon KY, Kim SH, Park KT, Chung JS, Lee WS, Lee SM, Hyun MS, Kim H, Ryoo HM, Bae SH, Joo YD.

Transfusion. 2015 Jul;55(7):1613-20. doi: 10.1111/trf.13036. Epub 2015 Mar 11.

PMID:
25764017
3.

Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.

Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Leger CS, Ramadan KM, Barnett MJ, Foltz LM, Vickars LM.

Hematol Oncol. 2010 Mar;28(1):40-8. doi: 10.1002/hon.902.

PMID:
19557769
5.

A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood.

Ladenstein R, Peters C, Minkov M, Emminger-Schmidmeier W, Mann G, Höcker P, Hawliczek R, Rosenmayr A, Fink FM, Niederwieser D, Gadner H.

Klin Padiatr. 1997 Jul-Aug;209(4):201-8.

PMID:
9293451
6.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
7.

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group.

Ann Hematol. 2003 Jun;82(6):336-42. Epub 2003 May 1.

PMID:
12728337
8.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.

Lee JH, Lee JH, Lim SN, Kim DY, Kim SH, Lee YS, Kang YA, Kang SI, Jeon MJ, Seol M, Seo EJ, Chi HS, Park CJ, Jang S, Yun SC, Lee KH.

Bone Marrow Transplant. 2010 Mar;45(3):450-7. doi: 10.1038/bmt.2009.190. Epub 2009 Aug 10.

PMID:
19668236
9.

Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.

van der Straaten HM, van Biezen A, Brand R, Schattenberg AV, Egeler RM, Barge RM, Cornelissen JJ, Schouten HC, Ossenkoppele GJ, Verdonck LF; Netherlands Stem Cell Transplant Registry "TYPHON".

Haematologica. 2005 Oct;90(10):1339-45.

10.

Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.

Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R, Van Rhee F, Barlogie B, Anaissie EJ.

Bone Marrow Transplant. 2006 May;37(9):857-64.

PMID:
16532017
11.

Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation.

Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J, Forman SJ.

Bone Marrow Transplant. 2008 Dec;42(12):799-805. doi: 10.1038/bmt.2008.262. Epub 2008 Sep 1.

PMID:
18762767
12.

Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma.

Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R, Andresen S, Sweetenham J, Kalaycio M, Copelan E.

Biol Blood Marrow Transplant. 2008 Nov;14(11):1239-44. doi: 10.1016/j.bbmt.2008.08.009.

13.

IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.

Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ, Nantel SH, Toze CL, Hogge DE, Forrest DL, Song KW, Power MM, Nitta JY, Dai Y, Smith CA.

Biol Blood Marrow Transplant. 2009 Feb;15(2):205-13. doi: 10.1016/j.bbmt.2008.11.015.

14.
15.

Introduction of the oncological pediatric risk of mortality score (O-PRISM) for ICU support following stem cell transplantation in children.

Schneider DT, Lemburg P, Sprock I, Heying R, Göbel U, Nürnberger W.

Bone Marrow Transplant. 2000 May;25(10):1079-86.

16.

Serum ferritin and survival of renal transplant recipients: a prospective 10-year cohort study.

Herget-Rosenthal S, Gerken G, Philipp T, Holtmann G.

Transpl Int. 2003 Sep;16(9):642-7. Epub 2003 May 6.

17.

Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.

Blau IW, Basara N, Bischoff M, Günzelmann S, Römer E, Kirsten D, Schmetzer B, Kiehl MG, Fauser AA.

Bone Marrow Transplant. 2000 Jan;25(1):41-5.

19.

Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes.

Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA, Pagliuca A, Cornelissen JJ, Schouten HC, Carreras E, Finke J, van Biezen A, Brand R, Niederwieser D, Gluckman E, de Witte TM; Subcommittee for Myelodysplastic Syndromes of the Chronic Leukaemia Working Group of the European Blood and Marrow Transplantation Group.

Blood. 2002 Jun 15;99(12):4370-8.

20.

Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.

Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2006 Jan;37(2):183-9.

PMID:
16299545

Supplemental Content

Support Center